Optimising cefepime dosing in intensive care: the pharmacokinetics of extended (prolonged) infusions.

Phase 4

Recruiting

• Conditions: intensive care sepsis; Infection - Other infectious diseases

• Registration Number: ACTRN12609000069257
• Lead Sponsor: The Alfred

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-01-28
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

An adult intensive care patient who: Has been prescribed cefepime according to The Alfred Intensive Care Unit (ICU) Antibiotic Guidelines (ie. after 7 days of hospital admission and requiring empiric or directed anti-microbial treatment); Is likely to remain in ICU for at least three days from enrolment; Has an arterial line already in situ for blood sampling.

Exclusion Criteria

1. Any documented allergy or adverse reaction to cefepime or other cephalosporin antibiotic or significant / serious adverse reaction to other beta-lactam or monobactam antibiotics which would normally preclude the prescribing of cefepime according to the Alfred ICU Antibiotic Guidelines.
2. Moderate to severe renal impairment (calculated estimated glomular filtration ratre (eGRF) <30mL/min at enrolment) or need for continous renal replacement therapy or intermittent heamodialysis.
3. Patients with significant burns (ie. greater than 15% body surface area)
4. Patients with extracorporeal circuits (eg. extracorporeal membranous oxygenation, ventricular assist devices)
5. All transplant patients including solid organ and bone marrow transplants
6. Pregnancy
7. Inclusion in other study protocols which preclude enrolment in this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified